BioSpace News Archive

The demand within the global chemotherapy-induced myelosuppression treatment market is growing alongside advancements in research pertaining to the bone marrow.

Cerner Corporation (Nasdaq: CERN), a global health care technology company, today announced that its Board of Directors declared a cash dividend to stockholders of $0.22 per issued and outstanding share, up 22% from the prior quarterly dividend of $0.18. The cash dividend will be payable on Jan. 12, 2021, to shareholders of record as of the close of business on Dec. 28, 2020. Cerner intends to pay regular quarterly cash dividends, with fu

The National Eating Disorders Association (NEDA) provides a critical grant through NEDA’s Feeding Hope Fund to support the Barriers to Treatment Access Study, led by Project HEAL in partnership with the Eating Anxiety Treatment (EAT) Lab at the University of Louisville . Eating disorders have some of the most complex and pervasive barr

CONTESSA Achieved Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved Progression-free Survival (PFS) Versus the Approved Dose of Capecitabine Alone (Hazard Ratio=0.716; p=0.003) Median PFS Was 9.8 Months for Tesetaxel Plus a Reduced Dose of Capecitabine Versus 6.9 Months for the Approved Dose of Capecitabine Alone, an Improvement of 2.9 Months

Global life sciences and diagnostics company advances environmental goals; invests more than $5M in sustainability-focused initiatives

Protech Home Medical Corp. (the “ Company ” or “ Protech ”) (TSXV: PTQ) (OTCQX: PTQQF), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, today announced that it will be presenting at the 13th annual LD Micro Main Event investor conference December 14 th at 11am EDT/ 8am PDT. Greg Crawford, CEO of Protech will be presenting to a live, virtual audience. Webcasted Presentation Event:

AGS Health, a leader in revenue cycle management services for major healthcare providers across the U.S. today announced it has been recognized by KLAS ® Research as a “consistent high performer” in their report, “Outsourced Codin

– Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment – – Statistically Significant Difference of Duration of Immune Response of NPS vs. Control: p=0.000094 - – Data to be Presented Today at the San Antonio Breast Cancer Symposium - NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broa

Proteor, a France-based international group specialized in prosthetic and orthotic solutions, has successfully completed its acquisition of American brand Freedom Innovations and the major part of the product portfolio from Ottobock. With this acquisition, the Proteor group is fueling its strategy to be a glob

- The electrophysiology (EP) segment is poised to have substantial growth through 2025 and beyond according to various industry reports. Electrophysiology is the biomedical field that deals with the study of electric activity in the body. Electrophysiology includes